Fig. 2

In vivo antitumor activity of BCMA-CD28-IL15 CAR-NK cells in the MM.1S-Luc transplanted NCG mouse model. (A) Schematic diagram of the mouse in vivo study. The NCG mice received an IV injection of 2.0 × 10⁶ MM.1S-Luc cells on day 0. Nine days after tumor inoculation, the mice were randomly divided into three groups (n = 3 for the control and mock-NK groups; n = 4 for the BCMA-CD28-IL15 CAR-NK group) according to the average radiance of the bioluminescence imaging. The mice were intravenously administered cryoprotectant (a solvent control), mock-NK cells, and BCMA-CD28-IL15 CAR-NK cells on day 9. (B) Bioluminescence images on days 9, 13, 20, 27, and 34. (C) Statistical analysis of the bioluminescence intensity on different days (****, P < 0.001; ns, no significance). (D) Body weight of each group measured on different days (****, P < 0.0001; ns, no significance). (E) Kaplan–Meier survival curves of mice in vivo. A statistical analysis of survival between groups was performed using the log-rank test. Statistical significance in survival rates was obtained after Bonferroni correction for multiple comparisons (*, P < 0.05)